{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:13:37Z","timestamp":1750306417717,"version":"3.41.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.7759\/cureus.86249","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:12:00Z","timestamp":1750223520000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Spectrum of Breast Cancer Patients Presenting at a Tertiary Care Hospital in Sindh, Pakistan"],"prefix":"10.7759","author":[{"given":"Sara Khalid","family":"Memon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawaz A","family":"Dal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahak W","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qambar A","family":"Laghari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-20301-6_1","article-title":"Breast cancer statistics: recent trends","volume":"1152","author":"Ahmad A","year":"2019","unstructured":"Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019, 1152:1-7. 10.1007\/978-3-030-20301-6_1","journal-title":"Adv Exp Med Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-326","article-title":"Behavioral risk factors in breast cancer: can risk be modified?","volume":"8","author":"McTiernan A","year":"2003","unstructured":"McTiernan A. Behavioral risk factors in breast cancer: can risk be modified?. Oncologist. 2003, 8:326-34. 10.1634\/theoncologist.8-4-326","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Senkus E","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, et al.. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015, 26 Suppl 5:v8-30. 10.1093\/annonc\/mdv298","journal-title":"Ann Oncol"},{"key":"ref4","unstructured":"Breast cancer. (2021). Accessed. May 26, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.7","article-title":"Cancer statistics, 2000","volume":"50","author":"Greenlee RT","year":"2000","unstructured":"Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000, 50:7-33. 10.3322\/canjclin.50.1.7","journal-title":"CA Cancer J Clin"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.29289\/25945394202020190029","article-title":"Histopathological and immunohistochemical parameters of breast cancer cases analyzed in a reference laboratory","volume":"30","author":"Soares MC","year":"2020","unstructured":"Soares MC, Rodrigues IJM, Almeida ICT da S de, Assun\u00e7\u00e3o JVP, Monteiro AM, Dias J\u00fanior LB. Histopathological and immunohistochemical parameters of breast cancer cases analyzed in a reference laboratory. Mastology. 2020, 30:e20190029.","journal-title":"Mastology"},{"key":"ref7","article-title":"Correlation of hormone receptor and HER2\/neu expression with clinicopathologic parameters in primary breast tumors","volume":"17","author":"Shaikh F","year":"2016","unstructured":"Shaikh F, Jamal Q, Baig S, Hadi NI, Majeedet N. Correlation of hormone receptor and HER2\/neu expression with clinicopathologic parameters in primary breast tumors. Asian Pac J Cancer Prev. 2016, 17:3363-7.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref8","unstructured":"Correlation between hepcidin and procalcitonin and their diagnostic role in patients with COVID-19. (2023). Accessed. May 26, 2025: https:\/\/www.researchgate.net\/profile\/Alyaa-Alsaedi-2\/publication\/370254936_CORRELATION_BETWEEN_HEPCIDIN_AND_PROCALCIT...."},{"key":"ref9","article-title":"Her-2\/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease","volume":"19","author":"Ahmad A","year":"2009","unstructured":"Ahmad A, Bano U, Gondal M, Khan A. Her-2\/neu gene overexpression in breast carcinoma and its association with clinicopathological characteristics of the disease. J Coll Physicians Surg Pak. 2009, 19:297-9.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.905832","article-title":"Recent progress on therapeutic vaccines for breast cancer","volume":"12","author":"Zhang L","year":"2022","unstructured":"Zhang L, Zhou X, Sha H, Xie L, Liu B. Recent progress on therapeutic vaccines for breast cancer. Front Oncol. 2022, 12:905832. 10.3389\/fonc.2022.905832","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.11.4411","article-title":"Prevalence, risk factors and disease knowledge of breast cancer in Pakistan","volume":"15","author":"Asif HM","year":"2014","unstructured":"Asif HM, Sultana S, Akhtar N, Rehman JU, Rehman RU. Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev. 2014, 15:4411-6. 10.7314\/apjcp.2014.15.11.4411","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.231","article-title":"Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients","volume":"6","author":"Kondov B","year":"2018","unstructured":"Kondov B, Milenkovikj Z, Kondov G, et al.. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. Open Access Maced J Med Sci. 2018, 6:961-7. 10.3889\/oamjms.2018.231","journal-title":"Open Access Maced J Med Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3677-y","article-title":"Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers","volume":"11","author":"Hashmi AA","year":"2018","unstructured":"Hashmi AA, Mahboob R, Khan SM, et al.. Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers. BMC Res Notes. 2018, 11:574. 10.1186\/s13104-018-3677-y","journal-title":"BMC Res Notes"},{"key":"ref14","article-title":"Molecular subtypes of breast cancer by immunohistochemical profiling","volume":"16","author":"Gulzar R","year":"2018","unstructured":"Gulzar R, Shahid R, Saleem O. Molecular subtypes of breast cancer by immunohistochemical profiling. Int J Pathol. 2018, 16:129-132.","journal-title":"Int J Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2019.11.021","article-title":"Molecular classification of breast cancer: a retrospective cohort study","volume":"49","author":"Al-Thoubaity FK","year":"2020","unstructured":"Al-Thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg (Lond). 2020, 49:44-8. 10.1016\/j.amsu.2019.11.021","journal-title":"Ann Med Surg (Lond)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson L","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022, 95:20211033. 10.1259\/bjr.20211033","journal-title":"Br J Radiol"},{"key":"ref17","article-title":"Histological and molecular classification of breast cancer: what do we know?","volume":"12","author":"Nascimento RG do","year":"2020","unstructured":"Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know?. Mastology. 2020, 12:1-8.","journal-title":"Mastology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5146\/tjpath.2012.01095","article-title":"Correlation of hormone receptors with Her-2 neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia","volume":"28","author":"Arafah M","year":"2012","unstructured":"Arafah M. Correlation of hormone receptors with Her-2 neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji Derg. 2012, 28:38-43. 10.5146\/tjpath.2012.01095","journal-title":"Turk Patoloji Derg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-017-0170-5","article-title":"Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es Salaam, Tanzania","volume":"12","author":"Mwakigonja AR","year":"2017","unstructured":"Mwakigonja AR, Lushina NE, Mwanga A. Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es Salaam, Tanzania. Infect Agent Cancer. 2017, 12:60. 10.1186\/s13027-017-0170-5","journal-title":"Infect Agent Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1920","article-title":"HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care","volume":"17","author":"Fabi A","year":"2011","unstructured":"Fabi A, Di Benedetto A, Metro G, et al.. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011, 17:2055-64. 10.1158\/1078-0432.CCR-10-1920","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9660-2","article-title":"HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information","volume":"109","author":"Ryd\u00e9n L","year":"2008","unstructured":"Ryd\u00e9n L, Landberg G, St\u00e5l O, Nordenskj\u00f6ld B, Fern\u00f6 M, Bendahl PO. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat. 2008, 109:351-7. 10.1007\/s10549-007-9660-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.119580","article-title":"Metastatic breast cancer with HER2\/neu-positive cells tends to have a morbid prognosis","volume":"131","author":"Emi Y","year":"2002","unstructured":"Emi Y, Kitamura K, Shikada Y, Kakeji Y, Takahashi I, Tsutsui S. Metastatic breast cancer with HER2\/neu-positive cells tends to have a morbid prognosis. Surgery. 2002, 131:S217-21. 10.1067\/msy.2002.119580","journal-title":"Surgery"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40066","article-title":"Luminal B, human epidermal growth factor receptor 2 (HER2\/neu), and triple-negative breast cancers associated with a better chemotherapy response than luminal A breast cancers in postneoadjuvant settings","volume":"15","author":"Hashmi AA","year":"2023","unstructured":"Hashmi AA, Bukhari U, Najam J, et al.. Luminal B, human epidermal growth factor receptor 2 (HER2\/neu), and triple-negative breast cancers associated with a better chemotherapy response than luminal A breast cancers in postneoadjuvant settings. Cureus. 2023, 15:e40066. 10.7759\/cureus.40066","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34656","article-title":"The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01)","volume":"129","author":"Neuman HB","year":"2023","unstructured":"Neuman HB, Schumacher JR, Edge SB, et al.. The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01). Cancer. 2023, 129:1351-60. 10.1002\/cncr.34656","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376331-clinicopathological-spectrum-of-breast-cancer-patients-presenting-at-a-tertiary-care-hospital-in-sindh-pakistan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:12:04Z","timestamp":1750223524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376331-clinicopathological-spectrum-of-breast-cancer-patients-presenting-at-a-tertiary-care-hospital-in-sindh-pakistan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.86249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}